title: Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats.
abstract: Two new potent allosteric effectors of hemoglobin, RSR-4 [2-[4-[[(3,5-dichloroanilino)carbonyl]-methyl]phenoxy]-2- methylpropionic acid] and RSR-13 [2-[4-[[(3,5-dimethlanilino)carbonyl]methyl]-phenoxy]-2-methylp rop ionic, are compared to the previously reported compounds L3,5 and L3,4,5 [Lalezari, I., Lalezari, P., Poyart, C., Marden, M., Kister, J., Bohn, B., Fermi, G., & Perutz, M. F. (1990) Biochemistry 29, 1515]. Unlike L3,5 and L3,4,5, RSR-4 and RSR-13 are less impeded by physiological concentrations of serum albumin. RSR-4 has also been shown to be more effective than L3,5 in shifting the allosteric equilibrium of bovine Hb toward the low-affinity T-state. X-ray crystal studies show that both RSR-4 and RSR-13 bind to only one pair of symmetry-related sites in the Hb central water cavity whereas previous studies on L3,5 and L3,4,5 demonstrated a second pair of symmetry-related binding sites near Arg 104 beta. Three major interactions between these allosteric effectors and Hb include the acid group with the guanidinium group of C-terminal Arg 141 alpha, the effector's amide oxygen with the ammonium ion of Lys 99 alpha, and the phi electrons of the halogenated or methylated aromatic ring and Asn 108 beta. No explanation has been found for the difference in number of binding sites observed for RSR-4 and RSR-13 (two sites) compared to L3,5 and L3,4,5 (four sites); also no correlation has been made between the number of binding sites and degree of allosteric shift in the oxygen equilibrium curve.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medical Chemistry, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0540.
authors.forename: D J
authors.initials: DJ
authors.lastname: Abraham
authors.forename: F C
authors.initials: FC
authors.lastname: Wireko
authors.forename: R S
authors.initials: RS
authors.lastname: Randad
authors.forename: C
authors.initials: C
authors.lastname: Poyart
authors.forename: J
authors.initials: J
authors.lastname: Kister
authors.forename: B
authors.initials: B
authors.lastname: Bohn
authors.forename: J F
authors.initials: JF
authors.lastname: Liard
authors.forename: M P
authors.initials: MP
authors.lastname: Kunert
mesh_terms: D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; D012856:4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D000494:Allosteric Regulation; D000495:Allosteric Site; D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D002417:Cattle; D004912:Erythrocytes / Q000378:metabolism*; D006454:Hemoglobins / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008958:Models, Molecular; D015394:Molecular Structure; D010108:Oxyhemoglobins / Q000378:metabolism*; D011422:Propionates / Q000494:pharmacology*; D011487:Protein Conformation; D051381:Rats; D013329:Structure-Activity Relationship; D014961:X-Ray Diffraction
chemical_list: D000814:Aniline Compounds; D006454:Hemoglobins; D010108:Oxyhemoglobins; D011422:Propionates; C077066:4-(2-(4-(((3,5-dichloroanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid); D012856:4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; C067396:efaproxiral; D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid